AUGUST 14, 2009

Big Pharma, the Polar Bear, and the Need to Specialize

How the Financial Crisis Is Saving Big Pharma

For over two decades, biotechnology companies have been perceived as the likely evolutionary winners in the race for survival and prosperity in the drug industry. The Credit Crunch, however, has drastically altered the landscape and has been seen by some as a life-line to Big Pharma. So, who will the winners be, and what strategies must they employ to thrive in these challenging times? In this article, Scisive Consulting examines five types of companies competing to be the fittest survivors and suggests some approaches to profiting from the opportunities resulting from the tighter competition for investment funds.

– Please request a free copy of the full article, presentation #0908, at This e-mail address is being protected from spambots. You need JavaScript enabled to view it